• refractory classic Hodgkin lymphoma (R/R cHL)
• R/R cHL - second line or more (L2) 1
• colorectal cancer (CRC)

 

• immune chekpoint inhibitors
• anti-PD-(L)1
• atezolizumab based treatment
• atezolizumab alone
• atezolizumab plus cometinib
• pembrolizumab based treatment
• pembrolizumab alone
• Immune checkpoint association
• durvalumab plus tremelimumab

• versus all
• vs chemotherapy
• vs Standard of Care (SoC)
• vs non active control
• vs BSC
• vs placebo
• vs VEGF(R) inhibitor
• vs regorafenib

• study list
• mapping
• overview
• meta-analysis
• forest plot
• NMA
• excluded

Top evidence (RCT only, high risk of bias excluded) Best available evidence (possibly low or very low) All RCTs All studies (RCT+OBS)

Comparator:  vs regorafenib; 
Risk of bias:  low;   some concerns;   high;  NA;